TickerFacts.

Endonovo Therapeutics, Inc. (ENDV): Revenue

Annual figures by period end, from SEC filings.

Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

$135.4K
Year ended 2022-12-31
-24.1%
3-year compound annual growth
$310.2K2018-12-31: $83.3K2019-12-31: $310.2K2020-12-31: $165.8K2021-12-31: $73.1K2022-12-31: $135.4K$135.4K
2018-12-31 Revenue (USD) 2022-12-31
Period endedRevenueChange YoYSource filing
2022-12-31$135.4K+85.2%2023-04-17, From 2022-01-01
2021-12-31$73.1K-55.9%2023-04-17, From 2021-01-01
2020-12-31$165.8K-46.5%2022-04-14, From 2020-01-01
2019-12-31$310.2K+272.5%2021-04-13, From 2019-01-01
2018-12-31$83.3Kn/a2020-05-04, From 2018-01-01